The European Drug–Drug Interaction ( EuroDDI ) Study Protocol: A Cross‐Country Comparison of Drug–Drug Interaction Prevalence in the Older Community‐Dwelling Population
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70092 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von John E Hughes und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Population Health, RCSI University of Medicine and Health Sciences, Dublin 2, Ireland. Hauptthemen laut MEDLINE: Drug Interactions. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Irish Research Council, Health Research Board, Government of Aragon.
Abstract (Originalsprache)
Background
Drug–drug interactions (DDIs), highly prevalent amongst the elderly, can lead to avoidable medication‐related harm. Cardiovascular and central nervous system (CNS) drugs are commonly implicated. To date, there is no consensus on how to measure DDIs, making comparisons across countries challenging.
Objective
To (i) establish a common data model (CDM) to measure DDI prevalence in the older (aged ≥ 70 years) community‐dwelling population of three European countries and (ii) compare and describe cardiovascular and CNS DDI prevalence rates across these countries.
Methods
This cross‐country study will apply a harmonised method of DDI identification and analysis using the WHO ATC classification system and national pharmacy claims data from three European countries (Ireland, Italy, Spain). Patients aged ≥ 70 years dispensed ≥ 2 medications during 2016 will be identified from each country's national database. ‘Severe’ cardiovascular and CNS DDIs (i.e., may result in a life‐threatening event/permanent detrimental effect) will be identified using the British National Formulary and Stockley's Drug Interactions. Two separate lists of ‘severe’ DDIs, per medications reimbursed, will be applied to each database: (i) DDIs relevant to each individual country and (ii) DDIs relevant to all three countries. DDIs will be defined as co‐dispensed (same day) and concomitantly (±7 days) dispensed.
Results
Descriptive statistics, including DDI prevalence and 95% confidence intervals, will be reported for each country. Prevalence will be pooled and compared across countries using random effects models and meta‐regression, where feasible.
Conclusion
The EuroDDI study will develop a harmonised method to measure and compare DDI prevalence across health‐related databases in Europe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Population Health, RCSI University of Medicine and Health Sciences, Dublin 2, Ireland.
- CIRFF, Center of Pharmacoeconomics and Drug Utilization Research, Department of Pharmacy, University of Naples Federico II, Naples, Italy.
- EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, Miguel Servet University Hospital, Zaragoza, Spain.
- Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Institute of Health Carlos III (ISCIII), Madrid, Spain.
- San Pablo Primary Care Health Centre, Aragon Health Service (SALUD), Zaragoza, Spain.
- Drug Utilization Work Group, Spanish Society of Family and Community Medicine (semFYC), Barcelona, Spain.
ORCID-Profile: John E Hughes, Enrica Menditto, Sara Mucherino, Valentina Orlando, Aida Moreno-Juste, Antonio Gimeno-Miguel, Mercedes Aza-Pascual-Salcedo, Francisca González-Rubio, Ignatios Ioakeim-Skoufa, Kathleen Bennett, Caitriona Cahir
Förderung
- Irish Research Council
- Health Research Board
- Government of Aragon
- Carlos III Institute of Health, Ministry of Science and Innovation (Spain), through the Network for Research on Chronicity, Primary Care, and Health Promotion…
- Ministry of University and Research Enlarged (Italy), through Partnership 8 (PE8) AGE-IT
- Gobierno de Aragón
- Instituto de Salud Carlos III
Zitieren
APA
Hughes, J. E., Menditto, E., Mucherino, S., Orlando, V., Moreno-Juste, A., Gimeno-Miguel, A., Poblador-Plou, B., Aza-Pascual-Salcedo, M., González-Rubio, F., Ioakeim-Skoufa, I., Bennett, K., & Cahir, C. (2025). The European Drug–Drug Interaction ( EuroDDI ) Study Protocol: A Cross‐Country Comparison of Drug–Drug Interaction Prevalence in the Older Community‐Dwelling Population. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70092
Vancouver
Hughes JE, Menditto E, Mucherino S, Orlando V, Moreno-Juste A, Gimeno-Miguel A, et al. The European Drug–Drug Interaction ( EuroDDI ) Study Protocol: A Cross‐Country Comparison of Drug–Drug Interaction Prevalence in the Older Community‐Dwelling Population. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70092
BibTeX
@article{Hughes2025,
author = {Hughes, John E and Menditto, Enrica and Mucherino, Sara and Orlando, Valentina and Moreno-Juste, Aida and Gimeno-Miguel, Antonio and Poblador-Plou, Beatriz and Aza-Pascual-Salcedo, Mercedes and González-Rubio, Francisca and Ioakeim-Skoufa, Ignatios and Bennett, Kathleen and Cahir, Caitriona},
title = {The European Drug–Drug Interaction ( EuroDDI ) Study Protocol: A Cross‐Country Comparison of Drug–Drug Interaction Prevalence in the Older Community‐Dwelling Population},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70092}
}
EUVIMED